🔗 Share this article

As the US proceeds with unprecedented adjustments to its vaccination schedules, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by questioning COVID-19 vaccinations throughout the pandemic and has focused upon possible fatalities following Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Vaccine Program

Agency leaders were set to reveal sweeping revisions to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US at odds with a large portion of the world with no evidence for public health gain. The planned update has been delayed until the next year.

Instead of the top vaccines chief, Høeg is scheduled to address the audience at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to run the division this year.

A Shift at the Agency

The acting appointment might represent a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a renewed priority upon rolling back previously authorized immunizations at the FDA.

Høeg has often pushed for discontinuing specific pediatric vaccine recommendations in the US so as to align more in line with Denmark, a country with nationalized medicine and a number of inhabitants approximately the population of the state of Wisconsin.

In her initial comments, she has kept her attention on immunizations – typically the purview of Dr. Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Expertise

Høeg has no apparent background in pharmaceutical research, oversight or leadership, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for overseeing the CDER, stated Jonathan Howard. “She’s never run a scientific study. She is not versed in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former directors of the center would “grasp legal statutes and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who ran the center have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock emphasized.

“The public just focuses on the new drug program, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and every single one have to be managed,” Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership element to the position, which supervises in excess of 5,000 employees. “It is a huge leadership role, if you execute it properly,” Woodcock added.

Official Statement and Controversial Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this selection indicates greater collaboration among FDA leaders on vaccines, a press secretary responded that the “concerns are based on incorrect presumptions”.

“Her experience aligns with the functions of her role,” the official said, noting the time Høeg spent guiding the agency head on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial one-day medication authorization process that allegedly troubled her former heads. “How are these medications being selected for this voucher program? Who is making the choices?” Howard said. “There’s a lot of lack of transparency occurring at the agency right now.”

Overall, he remarked, “the agency looks to be trending towards laxer regulations of pharmaceuticals, except for shots.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if troubling, history, Howard said. She released a research paper using unverified crowd-sourced reports to determine the frequency of myocarditis after COVID-19 immunization. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are riskier than they are.

Included in her “desired changes” for the incoming federal leadership included revising guidelines for novel immunizations and halting “non-essential” immunizations, she stated after the election on a podcast. At the FDA, Dr. Høeg has reportedly suggested preventing teenage boys from receiving COVID-19 vaccines.

“She’s an all-around true believer who begins with her preconceived notions and reverse-engineers to accommodate the science in a very deceptive, fraudulent fashion,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other contrarians, {like|